Improving how well escitalopram works for kids with anxiety
Improving the Effectiveness and Safety of Escitalopram in Pediatric Anxiety
['FUNDING_R01'] · UNIVERSITY OF CINCINNATI · NIH-10868603
This study is looking at how we can make the anxiety medication escitalopram work better and be safer for kids and teens by using their genetic information to personalize their treatment, so they can feel better with fewer side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CINCINNATI (nih funded) |
| Locations | 1 site (CINCINNATI, UNITED STATES) |
| Trial ID | NIH-10868603 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness and safety of escitalopram, a common medication for anxiety, specifically in children and adolescents. It aims to identify genetic factors that predict how well young patients respond to this treatment, which could help tailor medication dosing to individual needs. By conducting blinded, randomized trials, the study seeks to determine if personalized dosing based on genetic information can lead to better outcomes and fewer side effects for young patients suffering from anxiety disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and adolescents aged 0-21 years who are experiencing anxiety disorders.
Not a fit: Patients who do not have anxiety disorders or are outside the age range of 0-21 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for children and adolescents with anxiety disorders.
How similar studies have performed: While pharmacogenetic approaches have shown success in adult populations, this specific application in pediatric patients is novel and has not been previously tested.
Where this research is happening
CINCINNATI, UNITED STATES
- UNIVERSITY OF CINCINNATI — CINCINNATI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STRAWN, JEFFREY ROBERT — UNIVERSITY OF CINCINNATI
- Study coordinator: STRAWN, JEFFREY ROBERT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.